The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Hyperselection and ctDNA-guided treatment sequencing in CRC
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, comments on the concept of hyperselection and its potential impact on treatment sequencing in colorectal cancer, highlighting the use of liquid biopsy to identify patients with resistant mutations in their circulating tumor DNA (ctDNA). A subgroup analysis of the CR-SEQUENCE trial (2024-510967-41-00) is planned to determine if sequencing certain therapies improves its differential efficacy in patients with and without resistant mutations, which may inform the optimal treatment approach for each subgroup. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s been hype in the literature with three studies that have looked at hyperselection, molecular hyperselection through baseline liquid biopsy, ctDNA, resistant mutation panels. And we built up a liquid biopsy program within our study. So we will be able to test this question as well. And we will run a subgroup analysis with hyperselection negative patients, those that do not bear resistant mutations in their CT DNA, and in the subgroup that do carry resistant mutations, and see if in each of these two subgroups, sequence one improves its differential efficacy over sequence two...
There’s been hype in the literature with three studies that have looked at hyperselection, molecular hyperselection through baseline liquid biopsy, ctDNA, resistant mutation panels. And we built up a liquid biopsy program within our study. So we will be able to test this question as well. And we will run a subgroup analysis with hyperselection negative patients, those that do not bear resistant mutations in their CT DNA, and in the subgroup that do carry resistant mutations, and see if in each of these two subgroups, sequence one improves its differential efficacy over sequence two. That meaning that anti-EGFR first makes more sense in the negative hyperselection patients, which do not carry resistant mutations in their circulating DNA.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
